Immune checkpoint inhibitors (ICIs) were approved to treat advanced melanoma (AM) because of meaningful clinical benefit. These early data reported that ICI therapy is generally well tolerated, and despite symptoms, patients reported a high global health-related quality of life (HRQOL).

中文翻译：

---

免疫检查点抑制剂治疗对晚期黑色素瘤患者生活质量的影响：系统评价。

免疫检查点抑制剂（ICIs）因具有有意义的临床益处而被批准用于治疗晚期黑色素瘤（AM）。这些早期数据表明，ICI 疗法通常具有良好的耐受性，尽管有症状，患者仍报告了较高的全球健康相关生活质量 (HRQOL)。